Literature DB >> 24841413

Potential of hybrid ¹⁸F-fluorocholine PET/MRI for prostate cancer imaging.

Thomas de Perrot1, Olivier Rager, Max Scheffler, Martin Lord, Marc Pusztaszeri, Christophe Iselin, Osman Ratib, Jean-Paul Vallee.   

Abstract

PURPOSE: To report the first results of hybrid (18)F-fluorocholine PET/MRI imaging for the detection of prostate cancer.
METHODS: This analysis included 26 consecutive patients scheduled for prostate PET/MRI before radical prostatectomy. The examinations were performed on a hybrid whole-body PET/MRI scanner. The MR acquisitions which included T2-weighted, diffusion-weighted and dynamic contrast-enhanced sequences were followed during the same session by whole-body PET scans. Parametric maps were constructed to measure normalized T2-weighted intensity (nT2), apparent diffusion coefficient (ADC), volume transfer constant (K (trans)), extravascular extracellular volume fraction (v e) and standardized uptake values (SUV). With pathology as the gold standard, ROC curves were calculated using logistic regression for each parameter and for the best combination with and without PET to obtain a MR model versus a PETMR model.
RESULTS: Of the 26 patients initially selected, 3 were excluded due to absence of an endorectal coil (2 patients) or prosthesis artefacts (1 patient). In the whole prostate, the area under the curve (AUC) for SUVmax, ADC, nT2, K (trans) and v e were 0.762, 0.756, 0.685, 0.611 and 0.529 with a best threshold at 3.044 for SUVmax and 1.075 × 10(-3) mm(2)/s for ADC. The anatomical distinction between the transition zone and the peripheral zone showed the potential of the adjunctive use of PET. In the peripheral zone, the AUC of 0.893 for the PETMR model was significantly greater (p = 0.0402) than the AUC of 0.84 for the MR model only. In the whole prostate, no relevant correlation was observed between ADC and SUVmax. The SUVmax was not affected by the Gleason score.
CONCLUSION: The performance of a hybrid whole-body (18)F-fluorocholine PET/MRI scan in the same session combined with a prostatic MR examination did not interfere with the diagnostic accuracy of the MR sequences. The registration of the PET data and the T2 anatomical MR sequence data allowed precise localization of hypermetabolic foci in the prostate. While in the transition zone the adenomatous hyperplasia interfered with cancer detection by PET, the quantitative analysis tool performed well for cancer detection in the peripheral zone.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24841413     DOI: 10.1007/s00259-014-2786-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  45 in total

1.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.

Authors:  Mohsen Beheshti; Larisa Imamovic; Gabriele Broinger; Reza Vali; Peter Waldenberger; Franz Stoiber; Michael Nader; Bernhard Gruy; Guenter Janetschek; Werner Langsteger
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

2.  18F-choline PET/CT for initial staging of advanced prostate cancer.

Authors:  Fabrice Gutman; Vanessa Aflalo-Hazan; Khaldoun Kerrou; Françoise Montravers; Dany Grahek; Jean-Noël Talbot
Journal:  AJR Am J Roentgenol       Date:  2006-12       Impact factor: 3.959

3.  MRI-guided attenuation correction in whole-body PET/MR: assessment of the effect of bone attenuation.

Authors:  A Akbarzadeh; M R Ay; A Ahmadian; N Riahi Alam; H Zaidi
Journal:  Ann Nucl Med       Date:  2012-12-21       Impact factor: 2.668

4.  Clinical utility of apparent diffusion coefficient values obtained using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high b-value (2000 s/mm²) and standard high b-value (1000 s/mm²).

Authors:  Kazuhiro Kitajima; Satoru Takahashi; Yoshiko Ueno; Takeshi Yoshikawa; Yoshiharu Ohno; Makoto Obara; Hideaki Miyake; Masato Fujisawa; Kazuro Sugimura
Journal:  J Magn Reson Imaging       Date:  2012-02-27       Impact factor: 4.813

5.  Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT.

Authors:  Ivan Jambor; Ronald Borra; Jukka Kemppainen; Virva Lepomäki; Riitta Parkkola; Kirsti Dean; Kalle Alanen; Eveliina Arponen; Martti Nurmi; Hannu J Aronen; Heikki Minn
Journal:  Eur J Radiol       Date:  2012-02-18       Impact factor: 3.528

6.  Fluorocholine PET/CT in patients with prostate cancer: initial experience.

Authors:  Daniel T Schmid; Hubert John; Roland Zweifel; Tibor Cservenyak; Gerrit Westera; Gerhard W Goerres; Gustav K von Schulthess; Thomas F Hany
Journal:  Radiology       Date:  2005-05       Impact factor: 11.105

7.  Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging.

Authors:  Huadong Miao; Hiroshi Fukatsu; Takeo Ishigaki
Journal:  Eur J Radiol       Date:  2006-11-07       Impact factor: 3.528

8.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

Authors:  Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

9.  The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

Authors:  B J Krause; M Souvatzoglou; M Tuncel; K Herrmann; A K Buck; C Praus; T Schuster; H Geinitz; U Treiber; M Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-22       Impact factor: 9.236

10.  Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis.

Authors:  J Ren; Y Huan; H Wang; Y-J Chang; H-T Zhao; Y-L Ge; Y Liu; Y Yang
Journal:  Clin Radiol       Date:  2007-11-19       Impact factor: 2.350

View more
  15 in total

1.  Prostate cancer recurrence: can PSA guide imaging?

Authors:  P Mapelli; V Panebianco; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-09       Impact factor: 9.236

2.  Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.

Authors:  Verane Achard; Giorgio Lamanna; Antoine Denis; Thomas De Perrot; Ismini Charis Mainta; Osman Ratib; Christophe Iselin; Raymond Miralbell; Valentina Garibotto; Thomas Zilli
Journal:  Med Oncol       Date:  2019-06-12       Impact factor: 3.064

Review 3.  Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Authors:  M Picchio; P Mapelli; V Panebianco; P Castellucci; E Incerti; A Briganti; G Gandaglia; M Kirienko; F Barchetti; C Nanni; F Montorsi; L Gianolli; S Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-17       Impact factor: 9.236

Review 4.  Current Status of Hybrid PET/MRI in Oncologic Imaging.

Authors:  Andrew B Rosenkrantz; Kent Friedman; Hersh Chandarana; Amy Melsaether; Linda Moy; Yu-Shin Ding; Komal Jhaveri; Luis Beltran; Rajan Jain
Journal:  AJR Am J Roentgenol       Date:  2015-10-22       Impact factor: 3.959

Review 5.  Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.

Authors:  Paola Mapelli; Maria Picchio
Journal:  Nat Rev Urol       Date:  2015-08-11       Impact factor: 14.432

Review 6.  Molecular Imaging of Prostate Cancer.

Authors:  Andreas G Wibmer; Irene A Burger; Evis Sala; Hedvig Hricak; Wolfgang A Weber; Hebert Alberto Vargas
Journal:  Radiographics       Date:  2015-11-20       Impact factor: 5.333

Review 7.  PET/MRI in Oncological Imaging: State of the Art.

Authors:  Usman Bashir; Andrew Mallia; James Stirling; John Joemon; Jane MacKewn; Geoff Charles-Edwards; Vicky Goh; Gary J Cook
Journal:  Diagnostics (Basel)       Date:  2015-07-21

8.  Excellence is the Enemy of Good.

Authors:  John Buscombe
Journal:  World J Nucl Med       Date:  2014-09

9.  Molecular research in urology 2014: update on PET/MR imaging of the prostate.

Authors:  Axel Wetter
Journal:  Int J Mol Sci       Date:  2014-07-31       Impact factor: 5.923

Review 10.  Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging.

Authors:  Gaël Amzalag; Olivier Rager; Claire Tabouret-Viaud; Michael Wissmeyer; Electra Sfakianaki; Thomas de Perrot; Osman Ratib; Raymond Miralbell; Giampiero Giovacchini; Valentina Garibotto; Thomas Zilli
Journal:  Front Oncol       Date:  2016-03-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.